TG Therapeutics (FRA:NKB2) Cyclically Adjusted Book per Share: €1.29 (As of Mar. 2026)


FRA:NKB2 TG Therapeutics Inc FRA:NKB2
81 GF Score
Price €46.10
GF Value €48.41
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is TG Therapeutics Cyclically Adjusted Book per Share?

TG Therapeutics FRA:NKB2 -0.86% 81 Cyclically Adjusted Book per Share is €1.29 as of Mar. 2026. GuruFocus rates FRA:NKB2 with a GF Score™ of 81/100 and a GF Value™ of €48.41 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

TG Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €3.295. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, TG Therapeutics's average Cyclically Adjusted Book Growth Rate was 8.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of TG Therapeutics was 74.10% per year. The lowest was -52.50% per year. And the median was -11.70% per year.

As of today (2026-07-06), TG Therapeutics's current stock price is €46.10. TG Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €1.29. TG Therapeutics's Cyclically Adjusted PB Ratio of today is 35.74.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TG Therapeutics was 35.56. The lowest was 2.77. And the median was 14.61.


TG Therapeutics  (FRA:NKB2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

TG Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=46.10/1.29
=35.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of TG Therapeutics was 35.56. The lowest was 2.77. And the median was 14.61.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


TG Therapeutics Cyclically Adjusted Book per Share Related Terms


TG Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for TG Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics Cyclically Adjusted Book per Share Chart

TG Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.29 1.32 1.40 1.51 1.29

TG Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.30 1.24 1.25 1.29 1.29

FRA:NKB2 vs HALO, KYMR, PCVX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, TG Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TG Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TG Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where TG Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:NKB2
81GF Score
TG Therapeutics Inc FRA:NKB2
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TG Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TG Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.295/330.2130*330.2130
=3.295

Current CPI (Mar. 2026) = 330.2130.

TG Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 1.286 241.018 1.762
201609 0.924 241.428 1.264
201612 0.599 241.432 0.819
201703 1.415 243.801 1.917
201706 1.019 244.955 1.374
201709 0.945 246.819 1.264
201712 0.774 246.524 1.037
201803 0.897 249.554 1.187
201806 1.052 251.989 1.379
201809 0.741 252.439 0.969
201812 0.252 251.233 0.331
201903 0.192 254.202 0.249
201906 0.125 256.143 0.161
201909 -0.242 256.759 -0.311
201912 0.318 256.974 0.409
202003 -0.011 258.115 -0.014
202006 1.362 257.797 1.745
202009 1.124 260.280 1.426
202012 3.037 260.474 3.850
202103 2.644 264.877 3.296
202106 2.226 271.696 2.705
202109 1.852 274.310 2.229
202112 1.465 278.802 1.735
202203 1.070 287.504 1.229
202206 0.841 296.311 0.937
202209 0.698 296.808 0.777
202212 0.378 296.797 0.421
202303 0.172 301.836 0.188
202306 0.247 305.109 0.267
202309 1.019 307.789 1.093
202312 0.972 306.746 1.046
202403 0.953 312.332 1.008
202406 1.065 314.175 1.119
202409 1.111 315.301 1.164
202412 1.363 315.605 1.426
202503 1.388 319.799 1.433
202506 1.517 322.561 1.553
202509 3.333 324.800 3.389
202512 3.563 324.054 3.631
202603 3.295 330.213 3.295

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €1.29 mean?
TG Therapeutics (FRA:NKB2) has a Cyclically Adjusted Book per Share of €1.29 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on TG Therapeutics and its competitors.
Is TG Therapeutics' Cyclically Adjusted Book per Share too high?
TG Therapeutics' current Cyclically Adjusted Book per Share is €1.29. Overall, TG Therapeutics has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TG Therapeutics' Cyclically Adjusted Book per Share compare to HALO and KYMR?
TG Therapeutics' Cyclically Adjusted Book per Share of €1.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on TG Therapeutics and its competitors. TG Therapeutics's current Cyclically Adjusted Book per Share is €1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TG Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TG Therapeutics (FRA:NKB2) is currently considered Fairly Valued. The stock's GF Value™ is €48.41, compared to a current price of €46.10 — trading 4.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is €1.29. TG Therapeutics' overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For TG Therapeutics (FRA:NKB2), the current Cyclically Adjusted Book per Share is €1.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TG Therapeutics (FRA:NKB2) Overvalued in 2026?

Based on GuruFocus' analysis, TG Therapeutics stock appears to be undervalued. The current stock price of €46.10 is trading 4.8% below its estimated GF Value™ of €48.41. GuruFocus considers TG Therapeutics to be Fairly Valued.

Key valuation signals for FRA:NKB2:

  • Cyclically Adjusted Book per Share: €1.29
  • GF Value™: €48.41 vs. price of €46.10 (4.8% below fair value)
  • GF Score™: 81/100 with 8 warning signs

No single metric tells the full story. See the FRA:NKB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TG Therapeutics Business Description

Other Exchanges TGTX:USA1TGTX:Italy
Address 3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
81GF Score

Get the complete analysis for FRA:NKB2

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.10
Price
€48.41
GF Value